Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2011

View Archived Issues

GlaxoSmithKline reflects on achievements of third quarter 2011

In vitro and clinical data presented on Vitae Pharmaceuticals' renin inhibitor

Bristol-Myers Squibb offers report on third quarter 2011

Mibefradil dihydrochloride given with temozolomide in murine glioma model

Lilly initiates patient recruitment in phase III study of LY-2439821

Novartis obtains approval in Japan for new indication for Sandostatin LAR

Japanese authorities approve Beselna cream for actinic keratosis

Japanese researchers identify new biomarker for diagnosis/monitoring of RA

Angiogenesis inhibitor may enhance effects of therapy with oncolytic virus

Preclinical results reported for LEE-011 in human liposarcoma

Canadian and Chinese scientists disclose new flavonoid dimers

Novel compounds for diabetes prepared by Chinese team

biOasis enters agreement with Shire Human Genetic Therapies

Novel neuropeptide S receptor antagonists presented by U.S. team

Synairgen reports preclinical results of aerosolized IFN-beta use in viral pneumonia

Hanmi applies for E.U. orphan drug designation for LAPS-rhGH

New iron complexes for cancer disclosed by IHI Corporation

New nicotinic acetylcholine alpha7 receptor ligand prodrugs disclosed by Bristol-Myers Squibb

Bausch & Lomb completes patient recruitment in BOL-303259-X study

NIH discontinues use of tenofovir gel in HIV prevention study

European Commission approves Novartis' triple combination pill for high blood pressure

Japanese authorities expand approval of Pfizer's Diflucan

NICE recommends Eliquis for prevention of VTE in hip and knee surgery

Inspiration Biopharmaceuticals begins second pivotal study of OBI-1

Regeneron and Bayer commence Chinese phase III study of Eylea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Pharma industry faces long haul to get return on investment from AI
BioWorld Science
Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on...